New type of blood thinner fails to prevent repeat heart attacks
In LIBREXIA ACS, milvexian did not reduce heart attacks, strokes or heart deaths after acute coronary syndrome, though it also didn't increase serious bleeding.
29 August 2026
Clinical trials, drug development and research news
Tag
In LIBREXIA ACS, milvexian did not reduce heart attacks, strokes or heart deaths after acute coronary syndrome, though it also didn't increase serious bleeding.
29 August 2026
The SINGLE-AF trial found apixaban or rivaroxaban cut serious events from 1.5% to 0.5% in AF patients at intermediate stroke risk, without more major bleeding.
28 August 2026